Department of Cardiology, University Hospital Center "Mother Teresa"; Tirana-Albania.
Department of Occupational Health, Faculty of Medicine, University of Medicine; Tirana-Albania.
Anatol J Cardiol. 2022 Feb;26(2):118-126. doi: 10.5152/AnatolJCardiol.2021.486.
Global studies report a significant decline in ST-elevation myocardial infarction (STEMI) related hospitalization rates during the coronavirus disease 2019 (COVID-19) pandemic outbreak. However, there have been several divergent reports on hospital outcomes. In this study, we aim to investigate the impact of the COVID 19 outbreak on hospitalizations because of STEMI and in-hospital outcomes in Albania.
This was a retrograde study, collecting data for hospitalizations because of STEMI from March 9, (first COVID 19 case in our country) to April 30, 2020, (period of total lockdown) compared with the same period in 2019 at our center. The incidence rate ratio (IRR) was used to compare admissions because of STEMI and procedures and the risk ratio (RR) to compare mortality and other complication rates.
Admissions for STEMI declined during the COVID-19 period from a total of 217 in 2019 to 156 in 2020 (-28.1%) representing IRR 0.719 (p=0.033). PCIs also reduced from 168 procedures in 2019 to 113 in 2020 (-33%), representing an IRR of 0.67, p=0.021. The time from symptom onset to arrival at our intensive care unit was significantly higher in 2020 compared to 2019 (925.6±1097 vs. 438.7±385 minutes, p<0.001). The STEMI death rate during the pandemic compared to the control period was significantly increased to 14.1% vs. 7.8% (RR=1.91 p=0.037, but with no significant increase in primary PCI-STEMI death rate (8.9% vs. 4.8% RR=1.85 p=0.217). Cardiogenic shock also increased during the pandemic to 21.2% from 12.4% in 2019 (RR=1.70 p=0.025).
Hospitalizations and revascularization procedures for STEMI significantly reduced during the COVID-19 pandemic. We identified a substantial increase in the STEMI mortality rate and cardiogenic shock during the pandemic outbreak. Delayed timely reperfusion intervention might be responsible for the increased risk for complications.
全球研究报告显示,在 2019 年冠状病毒病(COVID-19)大流行期间,ST 段抬高型心肌梗死(STEMI)相关住院率显著下降。然而,关于医院结局的报告存在很大差异。在这项研究中,我们旨在研究 COVID-19 爆发对阿尔巴尼亚 STEMI 住院和院内结局的影响。
这是一项回顾性研究,从 2020 年 3 月 9 日(我国首例 COVID-19 病例)至 2020 年 4 月 30 日(全面封锁期间),收集我院因 STEMI 住院的数据,并与同期 2019 年进行比较。采用发病率比值(IRR)比较 STEMI 住院和介入治疗的入院率,采用风险比(RR)比较死亡率和其他并发症发生率。
COVID-19 期间,STEMI 住院患者从 2019 年的 217 例降至 2020 年的 156 例(下降 28.1%),IRR 为 0.719(p=0.033)。2019 年行 PCI 治疗 168 例,2020 年降至 113 例(下降 33%),IRR 为 0.67,p=0.021。与 2019 年相比,2020 年症状发作至入住我院重症监护病房的时间明显延长(925.6±1097 分钟比 438.7±385 分钟,p<0.001)。与对照期相比,大流行期间 STEMI 死亡率显著升高至 14.1%比 7.8%(RR=1.91,p=0.037),但直接 PCI-STEMI 死亡率无显著升高(8.9%比 4.8%,RR=1.85,p=0.217)。大流行期间心源性休克也从 2019 年的 12.4%增加至 21.2%(RR=1.70,p=0.025)。
COVID-19 大流行期间,STEMI 住院和血运重建治疗显著减少。我们发现大流行期间 STEMI 死亡率和心源性休克显著增加。延迟及时再灌注干预可能是导致并发症风险增加的原因。